Highlights

Yes, [I prescribe midostaurin as maintenance therapy] only if they don’t proceed to a stem cell transplant, yes. I can only prescribe it as maintenance for those who are treated with chemotherapy only. So, the majority of my patients will go on to stem cell transplant. So, I would only give it to those who are elderly, and yes, it wouldn’t be for everyone because the majority who are young, who are FLT3 mutated, unless they’ve got an NPM1 mutation, they would go for stem cell transplant in first remission. If they’ve got an NPM1 mutation I would monitor MRD, and then I would continue them on the midostaurin.

I’d be happy with a second-generation FLT3 inhibitor. One of them seems to be a little bit more efficacious if TKD mutation is present, so I quite like gilteritinib, but I would also be happy with quizartinib, it’s a really good drug, yes. So, either would be fine, and I can’t wait for at least one of them to come to market.